Our AI Platform offers high-success-rate, easily synthesizable, rapid, and precise early-stage drug development services and high-potential early-stage drug products for small-molecule development needs. Services include disease target and compound screening, structural optimization, cytotoxicity and animal pharmacotoxicology predictions, blood-brain barrier penetration rates, and cell or animal experiment validation. We also provide validated early-stage drug products to enrich R&D projects.

AI in drug development could speed up the design process and achieve high accuracy; however, it often produces structures similar to existing drugs, making it difficult to secure patents. Our platform combines AI smart compound design with molecular docking and key interaction analysis, effectively enhancing accuracy. In 4 years, the platform has developed 97 high-potential inhibitors covering 28 disease targets, demonstrating its patentability, effectiveness, and efficiency in drug design.

Our platform accelerates new drug development and improves success rates. We have completed multiple projects and are signing an NDA with a major Japanese pharma. By shortening R&D time and increasing success rates, we support Taiwan’s research capabilities and enhance technology transfer and clinical trial opportunities. With 97 high-potential inhibitors developed, our platform demonstrates effectiveness and efficiency in drug design, contributing to Taiwan’s pharmaceutical industry growth.